drugset / Trial / NCT01180153
Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate efficacy and safety of S-1 Oxaliplatin (SOX) regimen to patients with unresectable, metastatic or locally advanced biliary tract or ampullary adenocarcinoma.
Timeline
- Start
- 2010-08
- Primary completion
- 2012-08
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 50 mg | — |
| Subject | S-1 | Small molecule | 20 mg | — |
| Subject | S-1 | Small molecule | 25 mg | — |